Insulin-like growth factor I (IGF I)
Rapid Communication

Insulin-Like Growth Factor I Gene Expression in Vascular Cells
I nsulin-like growth factor I (IGF I) appears to play a key role in developmental growth 1 and in particular, to be a major mediator of the effects of growth hormone on postnatal growth. 2 IGF I messenger RNA (mRNA) transcripts have been localized in multiple tissues in both adult and fetal rats 3 as well as in human fetuses. 4 In the cardiovascular system, IGF I message has been localized to epicardium and coronary vessel walls by in situ hybridization, 5 and low level message has been detected in cardiac myocytes in the neonatal rat. 6 Resolution in these studies has been insufficient to detect specific cell types expressing the gene, in particular, as regards vascular endothelial and smooth muscle cells. Recent data have indicated a significant induction of IGF I message in the rat aorta after balloon injury 7 as well as in rat myocardium in a model of abdominal aortic coarctation hypertension. 8 -9 These studies, however, have not identified specific cell types expressing the IGF I gene. A recent report has localized IGF I mRNA to the smooth muscle layer of adult rat aorta but not to endothelium. 10 Although IGF I immunoreactivity has been detected in conditioned medium from both vascular smooth muscle cells (VSMC) 11 and endothelial cells, 12 there has been uncertainty as to whether this immunoreactivity represents release of previously internalized growth factor, a phenomenon occurring in endothelium, 13 or whether the growth factor is indeed produced by vascular cells. Because blood vessels are bathed in circulating somatomedins and both endothelial cells and VSMC possess specific high-affinity receptors for IGF I, 1415 the intense IGF I immunostaining present in regenerating blood vessels 16 may represent internalized growth factor, newly synthesized growth factor, or a combination of both.
As an initial approach to the general objective of defining the role of IGF I as a paracrine/autocrine factor in the control of growth in the vessel wall, we have characterized IGF I gene expression and protein secretion in cultured vascular endothelial and smooth muscle cells. Because the IGF I gene includes five coding exons 17 and several IGF I mRNA transcripts have been described containing one of at least three different 5' untranslated regions (class A,B,C) 18 and one of two different 3' domains, we have used a rat IGF I complementary DNA (cDNA) covering the common IGF I coding sequence. Hybridization studies demonstrated the presence of three primary IGF I mRNA transcripts in cultured rat aortic smooth muscle cells (RASM) and two primary IGF I mRNA transcripts in cultured bovine aortic endothelial cells (BAEC). Radioimmunoassay of conditioned medium from BAEC and RASM after separation of binding proteins by gel filtration chromatography demonstrated specific IGF I immunoreactivity. These findings demonstrate specific IGF I gene expression in vascular endothelial and smooth muscle cells and provide inferential evidence that vascular cells, through the production of IGF I, may have a broader potential than previously defined for exerting paracrine or autocrine growth effects both in the blood vessel wall as well as on nonvascular parenchymal cells.
Methods
Cell Culture
VSMC were isolated from rat thoracic aorta as described previously. 19 Cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 /xg/ml streptomycin. They were passaged one to two times a week by harvesting with trypsin-versene and seeding in 80-cm 2 flasks. For experiments, cells between passages 5 and 18 were seeded in 100-mm dishes (2X10 4 cells/cm 2 ), fed every other day, and used at 90-100% confluence (3-6 days). "
Endothelial cells were prepared from bovine aorta as described by Gimbrone. 20 Primary cultures were grown in DMEM supplemented with 10% fetal calf serum, glutamine and antibiotics and were passaged in 80-cm 2 flasks. Cells were used at passage levels 3-18 after replicate plating into 100-mm dishes. Purity of cultures was determined by acetylated low density lipoprotein (LDL) uptake 21 and only cultures free of any contaminating cells were used.
Radioimmunoassay
Ninety to 100% confluent cells were washed three times in serum-free medium and incubated in serum-free medium for 24 hours. Conditioned medium was dialyzed, lyophilized, and resuspended in 1 M acetic acid/0.025 M NaCl and was chromatographed using Biogel P30 polyacrylamide (Bio-Rad, Richmond, Calif.) columns. Fractions were assayed for IGF I immunoreactivity using a polyclonal anti-IGF I rabbit antiserum kindly provided by Dr. L. Underwood and J.J. Van Wyk through the National Hormone and Pituitary Program of the National Institute of Diabetes and Digestive and Kidney Diseases. A double antibody technique was used to precipitate bound counts using goat anti-rabbit antiserum and normal rabbit serum as a carrier.
Standard curves were generated using human recombinant IGF I (Amgen). IGF I immunoreactivity was expressed as a function of cell protein, which was determined by the method of Bradford.
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Binding Protein Assay
IGF I binding activity of conditioned medium after Biogel P30 chromatography was determined using a charcoal assay. 23 Briefly, 100 -fi\ aliquots from each column fraction were incubated with 125 I-IGF I (-20,000 cpm) in an assay buffer containing 0.25% (wt/vol) bovine serum albumin (BSA) in phosphatebuffered saline (PBS) at 4°C overnight, and unbound counts were precipitated using 0.25% (wt/vol) activated charcoal. Counts in the supernatant (bound by binding proteins) and in the pellet (bound by charcoal) were quantitated by automated gamma counting. Specific IGF I binding activity was expressed as a percentage of total binding activity. Nonspecific binding was determined by incubating 125 I-IGF I with activated charcoal in the absence of sample.
Insulin-Like Growth Factor I Gene Expression
Total RNA was extracted from cultured cells with the guanidium isothiocyanate/cesium chloride method 24 and enriched in polyadenylated RNA by two passages on an oligothymidilic acid cellulose column. 25 Ten to 20 fig of total RNA, polyadenylated RNA (A+), or A-RNA [RNA left after two passages on oligo(dT) cellulose] were denatured with dimethyl sulfoxide/glyoxal and size-fractionated by agarose gel electrophoresis before transfer to a nylon (Genescreen Plus, New England Nuclear, Boston, Mass.) membrane. Membranes were prehybridized at 65°C for 3-5 hours then hybridized for 24 hours in a solution containing 2.5 x Denhardt's, (lx Denhardt's: 0.02% Ficoll 400, 0.02% polyvinylpyrrolidone, and 0.02% BSA), 1 M NaCl, 2 mM EDTA, 0.1% sodium pyrophosphate, 1% sodium dodecyl sulfate (SDS), 100 /u,g/ml of denatured herring DNA, and 10 6 cpm/ml of a denatured IGF I cDNA probe. The IGF I cDNA was a rat 521 base pair fragment, which included the entire coding sequence for IGF I 26 and was kindly provided by Dr. G.I. Bell, Howard Hughes Medical Institute, University of Chicago. The cDNA was labeled by random-priming using [ 32 P]dCTP and Klenow enzyme. After hybridization filters were washed with 2x SSC (lx SSC 0.15 M NaCl, 0.015 M sodium citrate, pH 7) at room temperature, 2x SSC+1% SDS at 55°C and finally in 0.1 x SSC+0.1% SDS at 55°C before autoradiography. Only RNA with an optical density 260/280 ratio of 1.8-2.0 and with no signs of degradation on ethidium-bromide staining was used for experiments. Purity of RNA was additionally verified by hybridization to a /J-actin probe, which gave a clear band.
To further demonstrate IGF I gene expression in VSMC, solution hybridization/ribonuclease (RNase) protection assays were performed as described by Melton et al. 27 Forty micrograms total RNA were hybridized to a [ generated by T7 polymerase transcription of a linearized plasmid containing the rat exon 3 and adjacent intron sequences. The plasmid was kindly provided by Dr. P. Rotwein, Washington University School of Medicine. Hybridization was performed overnight in a solution containing 80% deionized formamide, 40 mM PIPES pH 6.4, 0.4 M NaCl, 1 mM EDTA, and 0.5 to 1 x 10 6 cpm riboprobe. After RNase digestion using 40 /xg/ml ribonuclease A and 50 units/ml ribonuclease Tl, samples were proteinase K treated, phenol extracted, ethanol precipitated, and analyzed on a denaturing polyacrylamide urea (sequencing) gel.
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FIGURE 1. Line graphs showing immunoreactive insulin-like growth factor I (IGF I) and IGF I binding proteins in rat aortic smooth muscle celts (RASM) conditioned medium.
Results
Both RASM and BAEC released IGF I as determined by radioimmunoassay of conditioned medium. Figure 1A demonstrates the elution profile of RASM-conditioned medium after dialysis, acidification, gel filtration chromatography, and radioimmunoassay. Two peaks of activity were present, and BAEC-conditioned medium yielded a similar profile. Serum-free medium and the third wash of serum-free medium before incubation of the cells in serum-free medium for 24 hours contained no detectable IGF I. Plasma and conditioned medium from various cell types including endothelial cells have been found to contain significant amounts of IGF I binding proteins that are known to cross-react in the radioimmunoassay by displacing tracer 125 I-IGF I from the anti-IGF I antibody. 28 We thus measured the binding protein activity of the chiomatographed fractions using a charcoal assay. Only one peak of binding protein activity was present in both endothelial cell-and VSMC-conditioned medium, and this peak corresponded closely to the first peak on the IGF I immunoassay profile ( Figure IB) . Furthermore, the elution profile of human recombinant 125 I-IGF I after acid chromatography corresponded to the second peak of IGF I immunoreactivity. Serial dilutions of the pooled fractions from the second peak of IGF I immunoreactivity from BAEC-and RASM-conditioned medium displaced iodinated tracer IGF I from antibody in a manner parallel to standard (not shown). These findings are consistent with the secretion by cultured BAEC and RASM of both IGF I binding proteins (first peak), and IGF I (second peak). When IGF I release was quantitated by pooling fractions from the second peak, VSMC in culture consistently secreted more IGF I than endothelial cells (Figure 2) .
Both endothelial and smooth muscle cells have been shown to possess specific high affinity receptors for IGF I.
14 -" Because endothelial cells in particular have been shown to internalize IGF I and to retain it intact for significant periods of time, 13 the possibility existed that IGF I release from these cells represented secretion of previously internalized growth factor. To demonstrate IGF I gene expression we performed Northern analysis of RNA extracted from RASM and BAEC. Using a phosphorus-32-labeled rat IGF I cDNA probe that included the entire IGF I coding sequence, we detected barely visible transcripts in total RNA extracted from RASM. However, when RNA was enriched in polyadenylated RNA by two cycles of oligo(dT) cellulose chromatography, three primary IGF I mRNA transcripts were detected after hybridization and exposure of autoradiograms for 1-2 days (Figure 3 ). The sizes of these transcripts estimated from the positions of 28S and 18S ribosomal RNAs on the ethidium-bromidestained gels were 8.2, 1.7, and 0.9-1.2 kb. To further provide evidence for IGF I gene expression in VSMC, solution hybridization/RNase protection assays were performed using a [ 2.1 kb and a minor transcript of 1.6 kb ( Figure 5 ). These transcripts were visible only after a long exposure of autoradiograms (10 days). No higher molecular weight IGF I mRNA transcripts were detected in endothelium. We could not perform RNase protection assays using endothelial RNA because the bovine IGF I cDNA has not been isolated. Discussion IGF I is a ubiquitous growth factor that was traditionally believed to be produced mainly in the liver, 28 ' 29 although its secretion has been demonstrated from a variety of cultured cell types. 29 - 31 The somatomedin "hypothesis" holds that one of the principle modes of action of growth hormone is to stimulate local tissue production of IGF I that then can act in an autocrine or paracrine manner to stimulate growth. 32^3 The relative importance of circulating somatomedin of presumed hepatic origin, acting as a traditional endocrine growth stimulator as opposed to locally synthesized and regulated IGF I, has not been determined.
In the cardiovascular system, there has been little information about the synthesis or effects of IGF I. In vitro data indicate that IGF I stimulates growth of both endothelial as well as smooth muscle cells. i 5 -34 In situ hybridization techniques have identified IGF I mRNA in epicardium and around coronary artery walls 5 as well as low levels in neonatal rat cardiac myocytes. 6 The resolution in these studies has not been sufficient to demonstrate specific cell types producing IGF I, in particular as regards endothelial cells and VSMC. A recent report has localized IGF I mRNA to the smooth muscle cell layer of rat aorta but not to endothelium. 10 Our data provide evidence that endothelial cells and VSMC, the two primary cellular components of the arterial wall, synthesize and secrete IGF I.
Prior data have indicated that IGF I acts as a potent comitogen with platelet-derived growth factor (PDGF) to stimulate VSMC growth.
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* PDGF appears to function essentially as a "competence" factor as defined by Stiles et al, 36 who demonstrated that quiescent BALB/c-3T3 cells exposed to PDGF became competent to enter the cell cycle but that progression through Gi into S phase required the presence of "progression" factors such as IGF I. Likewise, in VSMC, IGF I appears to function essentially as a progression factor, and exposure of VSMC to PDGF in the absence of IGF I elicits only a weak mitogenic response. 35 The possibility that VSMC may secrete their own progression factor was first raised by Clemmons et al, 37 who demonstrated that exposure of VSMC to PDGF caused an increase in an IGF I-like peptide found in VSMC-conditioned medium. Our findings demonstrate IGF I gene expression in VSMC, and we have presented preliminary results indicating that PDGF regulates IGF I gene expression in RASM. 38 These findings are consistent with an autocrine "loop" whereby VSMC may be induced to secrete their own progression activity under the influence of growth factors such as PDGF.
Intense IGF I immunostaining of both endothelial cells and VSMC is apparent in newly forming blood vessels, raising the possibility that it is fundamentally important in angiogenesis. 16 This may be related to induction of IGF I gene expression in proliferating vascular cells or increased internalization of circulating or locally produced somatomedin. Because endothelium internalizes IGF I and retains it intact for extended periods of time in vitro, 13 the endothelial cells may play a role in vascular cell growth in vivo through release of internalized circulating growth factor. However, our data are consistent with the possibility that IGF I gene expression and secretion is an intrinsic property of vascular endothelium and smooth muscle that is involved in local control of growth.
Changes in blood flow have been shown to induce endothelium-dependent remodeling of the vessel wall. 39 Induction of a chronic increase in vascular load is associated with marked increases in IGF I immunostaining of both endothelial cells and VSMC in rat femoral artery. 40 This raises the possibility that alterations in hemodynamic conditions regulate blood vessel wall IGF I content through increased uptake or local induction of IGF I gene expression. Alternatively, the increase in IGF I content may be secondary to arterial wall thickening.
The neointimal proliferative response after endothelial denudation of the rat femoral artery is accompanied by high levels of immunostainable IGF I in endothelial cells and VSMC. 41 Recent data have indicated an increase in IGF I mRNA levels in rat aorta after endothelial denudation. 7 Our data would support the hypothesis that endothelial cells and VSMC may be a primary source of IGF I in these injury models.
Several IGF I mRNA transcripts in various cell types and tissues have been identified by Northern analysis. The significance of these multiple transcripts, however, is not known.
-
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- 44 In VSMC, there are three primary IGF I transcripts, namely an 8.2,1.7, and 0.9-1.2 kb species. We have occasionally identified a 3.9 kb transcript in VSMC, the significance of which is unknown. These transcript sizes are similar to previously reported transcripts for IGF I. In particular, rat aorta has been found to contain IGF I transcripts sized at 7.8 and 0.8 kb, 45 and at 7.0, 1.8, and 1.0 kb. 10 In striking contrast, however, endothelial cells demonstrate one major transcript of 2.1 kb and a minor transcript of 1.6 kb. It is possible that the 1.6 kb endothelial transcript and the 1.7 kb smooth muscle transcript represent the same message, but the 2.1 kb transcript may be unique for endothelium. Liver has been found to contain a 2.1 kb transcript that may well represent the contribution of RNA originating from endothelial cells. 42 It is thus possible that some of the multiple IGF I transcripts described are cell type specific. Because the coding sequence for IGF I is highly conserved (95.7% homology between rat and human IGF I amino acid sequences 17 and 100% homology between human and bovine IGF I amino acid sequences 46 ), we think that the lower abundance of message seen in endothelium is not due to the use of a heterologous probe.
In summary, our findings demonstrate the secretion of IGF I and IGF I binding protein activity by cultured BAEC and VSMC, and the expression of three primary IGF I mRNA transcripts in VSMC and one major as well as one minor IGF I mRNA transcript in endothelial cells. IGF I may play a central role in the endogenous growth program of the blood vessel wall, and regulation of IGF I gene expression in vascular tissues may be key to understanding developmental and abnormal growth in the cardiovascular system. Furthermore, it is possible that the paracrine effects of IGF I originating from blood vessels may be extended to adjoining nonvascular parenchymal cells. In this respect the capillary endothelium, by virtue of its tremendous surface area and its ubiquitous distribution, may serve to modulate tissue levels of IGF I and thus play a regulatory role in the control of organ growth. We are at present exploring these possibilities.
